

Referral Criteria – ISLHD Breast Cancer MDT

	1: For PRIORITY discussion at MDT meeting <i>before surgery</i> where possible	2: For discussion at MDT meeting	3: Not for discussion at MDT meeting
New diagnosis	<p>1Ai: Candidates for neoadjuvant treatment, as defined by one or more of the following:</p> <ul style="list-style-type: none"> • Patient potentially eligible for neoadjuvant clinical trial • Locally advanced disease • Inflammatory breast cancer • Patient preference for breast conservation but borderline suitability at presentation 	<p>2Ai: <u>Complex</u> higher risk invasive breast cancer, eg:</p> <ul style="list-style-type: none"> • Larger tumour • High grade • Node positive • Triple negative <p>2Aii: <u>Complex</u> metastatic breast cancer requiring multidisciplinary input.</p>	<p>3Ai: Metastatic breast cancer not requiring multidisciplinary input.</p>
	<p>1Aii: Invasive breast cancer with high likelihood of genetic abnormality (e.g., early age diagnosis or strong family history)</p> <p>1Aiii: Patients with complex medical histories</p>	<p>2Bi: <u>Complex</u> Low–moderate risk invasive breast cancer</p> <ul style="list-style-type: none"> • Smaller tumour • Lower grade • Node negative • Hormone receptor positive / HER2 positive <p>2Bii: <u>Complex</u> Intermediate or high grade DCIS / LCIS</p>	
Re-discussion	<p>1Bi: Re-discussion of any of the above</p>	<p>2C: Complex New issue for patient previously treated or on treatment</p>	